Weekly review: Dupilumab, lebrikizumab FDA approved, plus much more - Contemporary Pediatrics

FDA approves dupilumab for adolescent CRSwNP, lebrikizumab for atopic dermatitis, and updated COVID-19 vaccines for all children. Research identifies metabolic markers linked to SIDS. Phase 2 data for LUM-201 in pediatric growth hormone deficiency discussed.